WHO model list of essential in vitro diagnostics: Difference between revisions
→Further reading: Global Action Plan for the Prevention and Control of NCDs |
WHO defines |
||
| Line 1: | Line 1: | ||
{{for|the lists for medicines|WHO Model List of Essential Medicines}} |
{{for|the lists for medicines|WHO Model List of Essential Medicines}} |
||
The '''WHO Model List of Essential In Vitro Diagnostics''', or '''WHO List of Essential Diagnostic Tests''' (EDL) is a [[World Health Organization]] (WHO) priority list of [[medical test]]s started in May 2018.<ref name="RDI">{{cite web |last1=Cam |first1=Yann Le |title=WHO Essential Medicines and in Vitro Diagnostics Lists: Why, What & How |url=https://www.rarediseasesinternational.org/wp-content/uploads/2020/05/6.-WHO-EMLEDL-Intro-presentation_YLC_19.05.20.pdf |website=Rarediseasesinternational.org |publisher=Rare Diseases International}}</ref> |
The '''WHO Model List of Essential In Vitro Diagnostics''', or '''WHO List of Essential Diagnostic Tests''' (EDL) is a [[World Health Organization]] (WHO) priority list of [[medical test]]s started in May 2018.<ref name="Bern2021">{{cite journal |last1=Bernabé-Ortiz |first1=Antonio |last2=Zafra-Tanaka |first2=Jessica H. |last3=Moscoso-Porras |first3=Miguel |last4=Sampath |first4=Rangarajan |last5=Vetter |first5=Beatrice |last6=Miranda |first6=J. Jaime |last7=Beran |first7=David |title=Diagnostics and monitoring tools for noncommunicable diseases: a missing component in the global response |journal=Globalization and Health |date=9 March 2021 |volume=17 |doi=10.1186/s12992-021-00676-6 |pmid=33750391 |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941936/ |issn=1744-8603}}</ref><ref name="RDI">{{cite web |last1=Cam |first1=Yann Le |title=WHO Essential Medicines and in Vitro Diagnostics Lists: Why, What & How |url=https://www.rarediseasesinternational.org/wp-content/uploads/2020/05/6.-WHO-EMLEDL-Intro-presentation_YLC_19.05.20.pdf |website=Rarediseasesinternational.org |publisher=Rare Diseases International}}</ref> It was revised in July 2019,<ref name="Bern2021"/><ref name="RDI"/> and a third edition was published in 2020.<ref name="Bern2021"/><ref name=icao>[https://www.icao.int/EURNAT/EUR%20and%20NAT%20Documents/COVID%2019%20Updates-%20CAPSCA%20EUR/02%20February%202021%20COVID19%20Updates/COVID19%20-%202021-02-01%20Updates/WHO%20Essential%20diagnostics%20list%20(EDL).pdf The selection and use of essential in vitro diagnostics: report of the third meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics], 2020 (including the third WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1031). Licence: CC BY-NC-SA 3.0 IGO.</ref> |
||
==Publications== |
==Publications== |
||
The WHO Model List of Essential In Vitro Diagnostics is a priority list of medical tests, which the WHO defines as are "one of the six building blocks of a health system".<ref name="Bern2021"/> |
|||
| ⚫ | The first edition was published by the WHO on 15 May 2018, and complements the [[WHO Model List of Essential Medicines]] (EML), which was published more than 40 years earlier.<ref name=" |
||
| ⚫ | The first edition was published by the WHO on 15 May 2018, and complements the [[WHO Model List of Essential Medicines]] (EML), which was published more than 40 years earlier.<ref name="Bern2021"/><ref name="Moussy2018">{{cite journal |last1=Moussy |first1=Francis Gabriel |last2=Berumen |first2=Adriana Velazquez |last3=Pai |first3=Madhukar |title=The WHO list of essential in vitro diagnostics: Development and next steps |journal=EBioMedicine |date=November 2018 |volume=37 |pages=1–2 |doi=10.1016/j.ebiom.2018.10.070 |pmid=30389503 |url=https://pubmed.ncbi.nlm.nih.gov/30389503/ |issn=2352-3964}}</ref> In it, essential diagnostic tests are defined as those "that satisfy the priority health care needs of the population and are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness."<ref name="Moussy2018"/> It lists 122 categories of tests; general laboratory tests and disease-specific tests such as for [[hepatitis B]] and [[hepatitis C|C]], [[HIV]], [[human papilloma virus|HPV]], [[malaria]], [[syphilis]] and [[tuberculosis]].<ref name="Bern2021"/><ref name="Moussy2018"/> A Strategic Group of Experts on In Vitro Diagnostics (SAGE IVD) is appointed by the WHO to advise on its development as it is regularly reviewed and expanded.<ref name="Moussy2018"/> A second edition was published in July 2019,<ref name="RDI"/> and a third in 2020.<ref name=icao/> |
||
The [[Indian Council of Medical Research]] produced its own version in 2019, a year after the first edition.<ref name="Vijay2021">{{cite journal |last1=Vijay |first1=Sonam |last2=Gangakhedkar |first2=Raman R |last3=Shekhar |first3=Chander |last4=Walia |first4=Kamini |title=Introducing a national essential diagnostics list in India |journal=Bulletin of the World Health Organization |date=1 March 2021 |volume=99 |issue=3 |pages=236–238 |doi=10.2471/BLT.20.268037 |pmid=33716346 |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941112/ |issn=0042-9686}}</ref> |
The [[Indian Council of Medical Research]] produced its own version in 2019, a year after the first edition.<ref name="Vijay2021">{{cite journal |last1=Vijay |first1=Sonam |last2=Gangakhedkar |first2=Raman R |last3=Shekhar |first3=Chander |last4=Walia |first4=Kamini |title=Introducing a national essential diagnostics list in India |journal=Bulletin of the World Health Organization |date=1 March 2021 |volume=99 |issue=3 |pages=236–238 |doi=10.2471/BLT.20.268037 |pmid=33716346 |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941112/ |issn=0042-9686}}</ref> |
||
Revision as of 17:53, 27 August 2021
The WHO Model List of Essential In Vitro Diagnostics, or WHO List of Essential Diagnostic Tests (EDL) is a World Health Organization (WHO) priority list of medical tests started in May 2018.[1][2] It was revised in July 2019,[1][2] and a third edition was published in 2020.[1][3]
Publications
The WHO Model List of Essential In Vitro Diagnostics is a priority list of medical tests, which the WHO defines as are "one of the six building blocks of a health system".[1]
The first edition was published by the WHO on 15 May 2018, and complements the WHO Model List of Essential Medicines (EML), which was published more than 40 years earlier.[1][4] In it, essential diagnostic tests are defined as those "that satisfy the priority health care needs of the population and are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness."[4] It lists 122 categories of tests; general laboratory tests and disease-specific tests such as for hepatitis B and C, HIV, HPV, malaria, syphilis and tuberculosis.[1][4] A Strategic Group of Experts on In Vitro Diagnostics (SAGE IVD) is appointed by the WHO to advise on its development as it is regularly reviewed and expanded.[4] A second edition was published in July 2019,[2] and a third in 2020.[3]
The Indian Council of Medical Research produced its own version in 2019, a year after the first edition.[5]
Content
For each group of tests, the EDL specifies the test's name, purpose, assay format and type of specimen.[6] Supporting WHO Guidelines or publications are linked and brands are not referenced.[6] The EDL includes recommendations of types of tests that should be available in community settings where there are no laboratories, such as for anaemia, malaria or pregnancy.[6] Laboratory tests such as those for testing for cancers are recommended for hospitals and laboratories.[6] There is also a section on tests that are no longer recommended.[7]
Community settings
Tests in community settings without laboratories are divided into general tests and tests that are disease-specific.[7] These include tests that are recommended for use in primary care units, doctors’ offices, community clinics, ambulatory care and at home such as for self-testing.[7]
Health care facilities with laboratories
Where there is a health care facility with laboratories, tests are divided into either general tests or disease-specific tests for clinical laboratories, and disease-specific tests for blood screening laboratories.[7]
References
- ^ a b c d e f Bernabé-Ortiz, Antonio; Zafra-Tanaka, Jessica H.; Moscoso-Porras, Miguel; Sampath, Rangarajan; Vetter, Beatrice; Miranda, J. Jaime; Beran, David (9 March 2021). "Diagnostics and monitoring tools for noncommunicable diseases: a missing component in the global response". Globalization and Health. 17. doi:10.1186/s12992-021-00676-6. ISSN 1744-8603. PMID 33750391.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b c Cam, Yann Le. "WHO Essential Medicines and in Vitro Diagnostics Lists: Why, What & How" (PDF). Rarediseasesinternational.org. Rare Diseases International.
- ^ a b The selection and use of essential in vitro diagnostics: report of the third meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2020 (including the third WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1031). Licence: CC BY-NC-SA 3.0 IGO.
- ^ a b c d Moussy, Francis Gabriel; Berumen, Adriana Velazquez; Pai, Madhukar (November 2018). "The WHO list of essential in vitro diagnostics: Development and next steps". EBioMedicine. 37: 1–2. doi:10.1016/j.ebiom.2018.10.070. ISSN 2352-3964. PMID 30389503.
- ^ Vijay, Sonam; Gangakhedkar, Raman R; Shekhar, Chander; Walia, Kamini (1 March 2021). "Introducing a national essential diagnostics list in India". Bulletin of the World Health Organization. 99 (3): 236–238. doi:10.2471/BLT.20.268037. ISSN 0042-9686. PMID 33716346.
- ^ a b c d "Brochure: The WHO model list of essential in vitro diagnostics (EDL)". www.who.int. 27 January 2021. Retrieved 27 August 2021.
- ^ a b c d "The selection and use of essential in vitro diagnostics - 2020". www.who.int. World Health Organization. pp. 272–352. Retrieved 20 August 2021.
Further reading
- Technical specifications for selection of essential in vitro diagnostics for SARS-COV-2 (PDF). World Health Organization. 14 June 2021.
- "Global Action Plan for the Prevention and Control of NCDs 2013-2020". www.who.int.